Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Long-Term Deferred Tax: 2020-2022

Historic Long-Term Deferred Tax for Maravai Lifesciences Holdings (MRVI) over the last 3 years, with Dec 2022 value amounting to $765.8 million.

  • Maravai Lifesciences Holdings' Long-Term Deferred Tax rose 0.33% to $773.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $773.7 million, marking a year-over-year increase of 0.33%. This contributed to the annual value of $765.8 million for FY2022, which is 5.24% down from last year.
  • Maravai Lifesciences Holdings' Long-Term Deferred Tax amounted to $765.8 million in FY2022, which was down 5.24% from $808.1 million recorded in FY2021.
  • In the past 5 years, Maravai Lifesciences Holdings' Long-Term Deferred Tax ranged from a high of $808.1 million in FY2021 and a low of $431.7 million during FY2020.
  • For the 3-year period, Maravai Lifesciences Holdings' Long-Term Deferred Tax averaged around $668.5 million, with its median value being $765.8 million (2022).
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first spiked by 87.19% in 2021, then declined by 5.24% in 2022.
  • Over the past 3 years, Maravai Lifesciences Holdings' Long-Term Deferred Tax (Yearly) stood at $431.7 million in 2020, then spiked by 87.19% to $808.1 million in 2021, then declined by 5.24% to $765.8 million in 2022.